Metabolomic, lipidomic and proteomic characterization of the type 1 diabetes pathogenesis
My research focus on the characterization of metabolites in the blood from type 1 diabetes (T1D) patients. Such metabolites may be used as surrogate markers of the function of the insulin producing beta cells in the pancreas and to study etiological pathways. This will allow better prediction of T1D risk and better disease staging and monitoring, with the ultimate goal to preserve and increase remaining beta-cell function, in pre- and new onset T1D patients.
1. Biomarkers of Progression in the At-Risk Setting for Type 1 Diabetes
Aim: The overall aim of the project is to evaluate the ability of molecular lipid species to more accurately predict risk of future T1D, and rate of progression using the cohorts collected through TrialNet and the Environmental Determinants of Diabetes in the Young (TEDDY) study. Collaborators: The TEDDY consortia, TrialNet, P. Meikle, J. Johannesen.
2. Metabolomic characterization of the TidBit cohort.
Aim: Investigation of the metabolome of blood samples collected through the TiDBiT study, a cohort consisting of 40 genetically high risk autoantibody-positive adolescents followed closely.
Collaborators: M. von Herrath, LL. Ahonen.
3. Variations in immune genes and quantities of lipids influence on beta cell function.
Aim: By combining ImmunoChip data and Lipididomics the aim is to investigate the role of metabolism in autoimmune diseases by modulating immune cell trafficking.